# Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis

> **NCT01777191** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 204 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Ixekizumab Auto-Injector
- **DRUG:** Ixekizumab Prefilled Syringe

## Key facts

- **NCT ID:** NCT01777191
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2014-05
- **Final completion:** 2015-05
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2019-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01777191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01777191, "Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01777191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*